SCHEMBL20183867

SCHEMBL20183867

CCn1c(=O)cc(Cl)c2cc(C(=O)N=C(C)N(C)C)ccc21

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.40
HPGD P15428 6/20 0.40
HTT P42858 5/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 6/20 0.37
LMNA P02545 3/20 0.37
ALDH1A1 P00352 6/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
PKM P14618 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
RECQL P46063 1/20 0.35
GFER P55789 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20183866 1.00 KDM4E (0.40) KDM4EHPGDHTTKMT2AMAPT
SCHEMBL20183578 0.79 KDM4E (0.53) KDM4EHPGDHTTKMT2AMAPT
SCHEMBL20183727 0.78 NPC1 (0.51) KDM4EHPGDHTTKMT2AMAPT
SCHEMBL20354256 0.76 KDM4E (0.37) KDM4EHPGDHTTKMT2AMAPT
SCHEMBL20354284 0.76 MAPT (0.46) KDM4EHPGDHTTKMT2AMAPT
SCHEMBL20183800 0.75 KDM4E (0.52) KDM4EHPGDHTTKMT2AMAPT
SCHEMBL20183699 0.74 KDM4E (0.43) KDM4EHPGDHTTKMT2AMAPT
SCHEMBL20195078 0.73 KDM4E (0.36) KDM4EHPGDHTTKMT2AMAPT
SCHEMBL28219292 0.72 KDM4E (0.39) KDM4EHPGDHTTKMT2AMAPT
SCHEMBL21476669 0.70 KDM4E (0.47) KDM4EHPGDHTTKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108137505-B Nitrogen-containing heterocyclic compound 富士胶片株式会社 2021-07-06 CN disclosed
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10633343-B2 2020-04-28 US disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
EP-3327004-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Fujifilm Corporation (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 KDM4E 1027/4885HPGD 2185/4885HTT 4000/4885
US-10696637-B2 Nitrogen-containing heterocyclic compound CXCL10, CCL5, CXCR3 KDM4E 3906/4885HPGD 581/4885HTT 3551/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 KDM4E 1027/4885HPGD 2185/4885HTT 4000/4885
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CXCL10, CCL5, CXCR3 KDM4E 3906/4885HPGD 581/4885HTT 3551/4885
US-10633343-B2 CXCL10, CCL5, CXCR3 KDM4E 3627/4885HPGD 1687/4885HTT 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.